D.Western Therapeutics Institute is primarily engaged in the discovery and development of new drugs. Co. is engaged in the research and development of new drugs and the licensing out newly developed drug candidate compounds to pharmaceutical companies at an early clinical stage. Co.'s drug pipeline includes ophthalmic solution 0.4% under the name of "GLANATEC" for glaucoma and ocular hypertension, an antiplatelet agent K-134 for arteriosclerosis obliterans and a protein kinase inhibitor H-1129 (WP-1303) for glaucoma and ocular hypertension. Co. also develops a multikinase inhibitor H-1337 for glaucoma and signaling inhibitors for neurological, cardiovascular and respiratory diseases.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.